Announcement of Marketing Authorization Transfer for Rabipur Intramuscular Injection
Updated Who we are
Announcement for Initiation of Phase III Trial of Glycerol Phenylbutyrate in Urea Cycle Disorders in Japan
Updated organization chart
Announcement of exclusive license agreement for development, manufacturing and sale of glycerol phenylbutyrate in Japan
Updated President's Message and Corporate Profile
Grifols and OrphanPacific start commercializing Lynspad™ [alpha-1 proteinase inhibitor] to treat alpha-1 antitrypsin deficiency
[IPM(Innovative Pharma Model) Introduction Video] CMIC Group Released "Creative Service to Support Drug Development Journey in Japan" Video
Announcement of Japan’s regulator approves Grifols’ Lynspad™ [alpha1-proteinase inhibitor] for the treatment of alpha-1 antitrypsin deficiency
OrphanPacific, Inc. Receives Manufacturing and Marketing Approval of
ORLADEYO Capsules 150mg for Suppression of HAE Attacks in Japan
[Short Educational Video] CMIC Group Released C-CAST: Executive Interview, Philippe Auvaro
- Recent changes and current opportunities in Japan’s Pharmaceutical market
- CMIC’s IPM (Innovative Pharma Model)
[Short Educational Video] CMIC Group Released Two C-CASTs on;
- Expedited Review Programs in Japan
- In-Country Clinical Caretaker (ICCC) for Clinical Trials in Japan
OrphanPacific Inc. measures to continue to serve the community while respecting the instructions from the government of the COVID-19
Response and Support During COVID-19 Pandemic
(Will be linked to CMIC Group website)
[Webinar Archive Available] Orphan drug development in Japan - How can we accelerate rare disease patients’ access to therapies? -
OrphanPacific Inc. measures to contain the further spread of the new corona-virus
Learn More about Japanese Market Entry
Announcement of Marketing Authorization Transfer and Product Name Change of DIAZOXIDE Capsules 25 mg "MSD"
OrphanPacific, Inc. Exhibited and Presented at World Orphan Drug Congress USA 2019
OrphanPacific, Inc. to Present at World Orphan Drug Congress USA 2019
